Gastroenterology Denial Appeal Automation: Overturning GI Prior Authorization Denials

Klivira's gastroenterology denial appeal automation platform empowers GI practices and health systems to efficiently overturn prior authorization denials for high-cost biologics, advanced imaging, and complex endoscopic procedures.

Prior authorization denials in gastroenterology pose significant challenges to revenue cycles, often stemming from complex step therapy requirements, evolving biosimilar policies, and detailed clinical documentation needs for chronic conditions. Manually managing these appeals diverts staff from patient care and can lead to lost revenue. Klivira provides a targeted solution.

The High Stakes of GI Prior Authorization Denials

Gastroenterology prior authorizations are high-volume, particularly for IBD biologics like Humira, Stelara, Skyrizi, and Entyvio, as well as Hepatitis C direct-acting antivirals and advanced imaging such as MRCP or CT enterography. Common denial reasons include failure to meet step therapy requirements, missing disease severity documentation (e.g., Mayo score for UC, CDAI for Crohn's), or gaps in pre-treatment screening for biologics, as outlined by ACG and AGA guidelines.

Frequent Gastroenterology Denial Triggers Requiring Appeals

Step therapy requirements for IBD biologics (e.g., requiring conventional therapy or TNF inhibitor trials first).
Payer mandates for biosimilar substitution over brand TNF inhibitors (e.g., infliximab biosimilar over Remicade).
Insufficient documentation of disease severity, such as missing Mayo score or CDAI, or TB/Hepatitis screening pre-biologic.
Gaps in fibrosis stage documentation or drug-drug interaction review for Hepatitis C DAAs (Epclusa, Mavyret).
Inappropriate-use criteria or insufficient prior workup for advanced imaging (MR enterography) or capsule endoscopy (CPT 91110).

Automating Gastroenterology Denial Appeals with Klivira

Klivira transforms the manual appeal process into an automated workflow, beginning with denial classification via normalized CARC/RARC taxonomy. Our platform intelligently selects the appropriate appeal pathway based on payer-specific policies, ensuring timely filing and adherence to documentation requirements for both medical and pharmacy benefit claims common in GI, such as for IBD biologics.

Key Automated Appeal Workflows for GI Practices

**FHIR-based Documentation Re-discovery:** Automatically pulls additional clinical evidence from the EMR, including new labs, imaging, or updated problem lists, to strengthen appeal packets.
**Payer-Template Appeal Letter Generation:** Composes appeal letters tailored to specific denial reasons and payer requirements, drafting clinician-reviewable letters for clinical-necessity cases with literature citations.
**Payer-Policy-Aware Pathway Selection:** Navigates complex appeal levels (first-level, second-level, peer-to-peer) and timely-filing windows specific to each payer and GI indication.
**Status Tracking and Escalation:** Provides automated tracking of appeal status with timely-filing window enforcement and escalation rules to prevent lost-to-follow-up cases.
**Outcome Capture and Feedback:** Records appeal outcomes in the EMR and feeds success patterns back into upstream PA submission processes for continuous improvement.

Enhancing GI Patient Access and Revenue Integrity

By automating gastroenterology denial appeal workflows, Klivira directly addresses the operational burden and financial impact of prior authorization denials. Our platform's integration with EMR systems facilitates the extraction of critical clinical data, such as IBD disease activity scores or Hepatitis C fibrosis stages, ensuring appeals are robust and evidence-based, aligning with ACG, AGA, and AASLD guidelines.

Frequently asked questions

How does Klivira handle step therapy denials for IBD biologics?

Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic. It automatically identifies if prior conventional therapies or biosimilar trials were attempted and documented in the EMR, helping to construct appeal letters that specifically address the payer's step therapy requirements.

Can Klivira automate appeals for advanced GI imaging procedures?

Yes, Klivira automates appeals for advanced imaging like MRCP or MR enterography. The platform pulls documentation to address common denial reasons such as missing clinical correlation, insufficient prior workup, or indications not meeting payer medical necessity criteria, ensuring comprehensive appeal packets.

What role does FHIR play in gastroenterology denial appeals with Klivira?

Klivira leverages SMART on FHIR to re-discover and extract additional clinical documentation from the EMR that may not have been in the original PA submission. This includes new notes, updated lab results (e.g., fibrosis stage for Hep C), or imaging reports, providing robust evidence for the appeal.

Does Klivira support appeals for both medical and pharmacy benefit GI drugs?

Yes, Klivira's platform is designed to manage appeals for gastroenterology drugs that fall under both medical and pharmacy benefits. This is crucial for biologics where administration mode (infusion vs. self-injection) can shift the benefit type, ensuring consistent appeal management regardless of the claim's origin.

How does Klivira ensure appeal letters are high quality and payer-specific?

Klivira uses a library of per-payer appeal letter templates that are dynamically assembled based on the specific denial reason and payer policy. For clinical-necessity appeals, it drafts a clinician-reviewable letter that includes relevant literature citations and clinical evidence, ensuring consistency and quality.